7 research outputs found
Recommended from our members
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable responses – was the only treatment option for patients with NSCLC whose tumors lacked targetable mutations. By contrast, immune checkpoint inhibitors have demonstrated distinctly durable responses and represent the advent of a new treatment approach for patients with NSCLC. Three immune checkpoint inhibitors, pembrolizumab, nivolumab and atezolizumab, are now approved for use in first- and/or second-line settings for selected patients with advanced NSCLC, with promising benefit also seen in patients with stage III NSCLC. Additionally, durvalumab following chemoradiation has been approved for use in patients with locally advanced disease. Due to the distinct features of cancer immunotherapy, and rapid progress in the field, clinical guidance is needed on the use of these agents, including appropriate patient selection, sequencing of therapies, response monitoring, adverse event management, and biomarker testing. The Society for Immunotherapy of Cancer (SITC) convened an expert Task Force charged with developing consensus recommendations on these key issues. Following a systematic process as outlined by the National Academy of Medicine, a literature search and panel voting were used to rate the strength of evidence for each recommendation. This consensus statement provides evidence-based recommendations to help clinicians integrate immune checkpoint inhibitors into the treatment plan for patients with NSCLC. This guidance will be updated following relevant advances in the field
A Study on Socio-Economic Status of Mango Growers in Bijnor District of Western Uttar Pradesh
Mango is a tropical and subtropical fruit crop grown in India over an area of 2258.13 thousand hectares with production of 21822.32 metric tons. The total area under mango cultivation in Uttar Pradesh is 265.62 thousand hectares with 4551.83 metric tons production 2017-18. In Bijnor district of Uttar Pradesh, mango grown 5.91 thousand hectares area with 118.09 metric tons production of mango in the same period. Mango grown in diverse agro climatic conditions faces differential biotic and abiotic stress limiting the production and productivity of mango that in influenced the economic condition of mango Growers. The purpose of the present study was to examine the socio-economic status of mango growers in Bijnor district of Western Uttar Pradesh. The result of the analysis shows that 39.09 percent of respondent fall within the age range of 46 to 60 years, general caste (53.64 percent), education level-literate (50.91 percent), family type-joint family (69.09 percent), family member-4 to 6 members (67.27), land holding size-above 5 hectare (50.91 percent), irrigation facilities-own (84.55 percent), 58.18 percent of respondents were engaged in farming activities only and 25.00 percent respondent were doing farming with business. 38.18 percent respondent got more than Rs 300000.00 annual income, 36.82 percent respondent have their own pumping set and electric motor and 53.64 respondent has not participated in any technical programme
Additional file 1: of The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Cancer Immunotherapy Guidelines- Lung Task Force Roster. (DOCX 13 kb
Additional file 2: of The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Comments from Member Open Review. (DOCX 14 kb
Presence of a widely disseminated Listeria monocytogenes serotype 4b clone in India
Details about the members of the Indian Listeria Consortium are provided in the Supplementary Data.Emerging Microbes and Infections (2016) 5, e55; doi:10.1038/emi.2016.55; published online 8 June 201